Review of forecast against actual business developments in 2013

 

 

 

 

 

 

 

 

 

 

Guidance for 2013 provided in:

 

 

Actual results 2012  € million

Forecast 2013 in Annual Report 2012

Q1/2013 Interim Report

Q2/2013 Interim Report

Q3/2013 Interim Report

Actual results 2013 € million

1

The actual figures for 2012 have been adjusted. More information can be found in Note (52) of the consolidated financial statements.

Merck Group

 

 

 

 

 

 

Sales

10,740.8

moderate organic growth

€ 10.7 – 10.9 billion

€ 10.7 – 10.9 billion

€ 10.7 – 10.9 billion

10,700.1
+4.2% org.

EBITDA pre one-time items

2,964.9

increase

€ 3.1 – 3.2 billion

€ 3.1 – 3.2 billion

€ 3.2 – 3.25 billion

3,253.3
+9.7%

Business free cash flow

2,969.3

moderate decrease

–

–

–

2,960.0
–0.3%

Merck Serono

 

 

 

 

 

 

Sales

5,995.8

moderate organic growth

moderate organic growth

moderate organic growth

moderate organic growth

5,953.6
+3.9% org.

EBITDA pre one-time items1

1,824.7

improvement

€ 1.9 – 2.0 billion

€ 1.9 – 2.0 billion

€ 1.9 – 2.0 billion

1,955.0
+7.1%

Business free cash flow1

1,880.2

moderate decrease

–

–

–

1,875.7
–0.2%

Consumer Health

 

 

 

 

 

 

Sales

472.6

stable

stable

stable

moderate organic growth

476.9
+5.6% org.

EBITDA pre one-time items1

66.8

slight increase

€ 70 – 75 million

€ 70 – 75 million

€ 73 – 77 million

72.5
+8.5%

Business free cash flow1

88.8

moderate decrease

–

–

–

83.9
–5.5%

Performance Materials

 

 

 

 

 

 

Sales

1,674.2

slight organic decline

stable

stable

stable

1,642.1
+3.0% org.

EBITDA pre one-time items1

741.9

remain on high level

€ 700 – 740 million

€ 730 – 750 million

€ 750 – 770 million

779.7
+5.1%

Business free cash flow1

798.1

moderate decrease

–

–

–

787.8
–1.3%

Merck Millipore

 

 

 

 

 

 

Sales

2,598.2

moderate organic growth

moderate organic growth

moderate organic growth

moderate organic growth

2,627.5
+5.5% org.

EBITDA pre one-time items1

614.4

growth in line with sales

€ 620 – 640 million

€ 620 – 640 million

€ 620 – 640 million

642.8
+4.6%

Business free cash flow1

511.3

moderate decrease

–

–

–

493.8
–3.4%

Corporate and Other

 

 

 

 

 

 

EBITDA pre one-time items1

–282.9

improvement

€ –210 million

€ –210 million

€ –210 million

–196.7
–30.5%